2月6日,美国礼来公司公开了2024年业绩,全年营收450.43亿美元,同比增长32%,其中四季度营收135.33亿美元,同比增长45%。期末净利润105.9亿美元,同比增长102%礼来的营收主要来自糖尿病,其中GLP-1类似物总营收达到217.19亿美元,约占礼来营收的一半。新上市的替尔泊肽表现非常抢眼,降糖版卖出115.40亿美元,减肥版49.26亿美元,合计164.66亿美元。虽然度拉糖肽...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.